Welcome to our dedicated page for Hydreight Tech news (Ticker: HYDTF), a resource for investors and traders seeking the latest updates and insights on Hydreight Tech stock.
Hydreight Technologies Inc. (HYDTF) regularly publishes news and corporate updates that reflect its role as a digital health and mobile clinic platform operating across all 50 U.S. states. Company announcements focus on platform expansion, treatment category launches, pharmacy and telehealth integrations, and operational milestones tied to its mobile clinical network and VSDHOne direct-to-consumer infrastructure.
Investors and observers following Hydreight’s news can expect coverage of financial and operational performance, such as revenue trends, product order volumes, and profitability metrics, as disclosed in quarterly updates. The company also reports on nurse network growth, license counts, and pharmacy order activity, which it uses as indicators of platform adoption and utilization across its ecosystem.
Hydreight’s news flow highlights developments in its multi-vertical healthcare model. Releases have described growth across categories including GLP-1 weight management, testosterone replacement therapy, peptides, NAD+ therapies, hair loss and skincare offerings, sexual health products, genetics and personalized genetic testing, and other wellness and longevity services. Additional updates cover expansions into at-home and preventive testing, such as the company’s entry into the at-home STI pre-screening market through an exclusive distribution agreement for rapid testing kits.
Corporate communications also address strategic initiatives, including enhancements to the VSDHOne platform, investments in modular architecture, pharmacy partnerships such as the stake in Perfect Scripts, and financing activities like convertible debenture offerings. Recognition in programs such as the Deloitte Technology Fast 500™ and the TSX Venture Exchange Top 50 is another recurring theme in Hydreight’s news.
For readers tracking HYDTF, the news page offers a centralized view of how Hydreight’s digital health infrastructure, mobile clinic network, and direct-to-consumer platforms are evolving over time. Regular updates provide context on the company’s operational metrics, treatment verticals, and strategic priorities within the U.S. digital health and wellness market.
Hydreight Technologies (HYDTF) has expanded its VSDHOne platform by launching Liraglutide, enhancing its GLP-1 weight management portfolio. The company's comprehensive GLP-1 offerings now include Semaglutide (weekly injectable), Tirzepatide (dual-action, weekly injectable), Liraglutide (daily injectable), and Sublingual & Buccal GLP-1s (needle-free administration).
The addition of Liraglutide introduces a stable, patent-free option amid increasing GLP-1 medication demand. The VSDHOne platform facilitates telehealth consultation, prescription, and nationwide delivery across 50 US states. With over 400 licenses sold across the U.S., Hydreight's platform supports multiple delivery methods including injectables, sublingual, and buccal options.
Notable achievements include ranking 56th on the 2024 Deloitte Technology Fast 500™, recognition as a Top 50 TSX Venture Exchange Company, and ranking 13th among Americas' Fastest Growing Companies by Financial Times in 2025.
Hydreight Technologies (HYDTF) has announced a strategic partnership with renowned endocrinologist Dr. Franklin Joseph to launch his successful weight-loss brand, 'Dr. Frank's Method,' in the United States through their VSDHOne telehealth platform.
The partnership combines Dr. Frank's GLP-1 weight-loss methodology, which has served over 500,000 global patients, with Hydreight's nationwide telehealth infrastructure. The program includes access to branded GLP-1 medications, specialist weight-loss nurses, and personalized lifestyle support.
Key partnership terms include:
- 50/50 profit-sharing structure
- Waived platform fees from Hydreight
- Committed monthly U.S. marketing spend from Dr. Frank
This collaboration targets the expanding U.S. weight-loss market, where over 42.4% of adults have obesity. The global weight-loss market is projected to exceed $400 billion by 2030, with GLP-1 prescriptions showing a 400% increase and spending rising by 500%.
Hydreight Technologies (OTCQB: HYDTF) has been named to the Financial Times list of The Americas' Fastest Growing Companies 2025, validating its remarkable growth trajectory in the digital health platform sector. The company has achieved a stunning 2,400% revenue growth from $400K to nearly $24M in just five years, while maintaining positive Adjusted EBITDA.
Ranked 56th on Deloitte's Technology Fast 500™ and 9th in Canada, Hydreight met strict criteria including: minimum revenue of $100,000 in 2020 and $1.5M in 2023, independent company status, and primarily organic growth. The company is expanding into high-growth sectors including:
- GLP-1 weight-loss medications
- Anti-aging therapies
- IV wellness
- At-home testing
- Chronic care management
The company plans to launch new offerings, scale M&A, and expand its national footprint in 2025, positioning itself as a leader in direct-to-consumer telehealth services across the U.S.
Hydreight Technologies (OTCQB: HYDTF) has expanded its VSDHOne telehealth platform by introducing new oral weight loss therapies across three delivery formats: sublingual, capsule, and tablet. The company, which operates a mobile clinical network across all 50 U.S. states, now offers multiple weight loss treatments including Semaglutide Sublingual, Sermorelin Sublingual, Advanced Weight Management Support Capsule, Metformin HCl ER Tablets, and Phentermine HCl Tablets.
With a network of over 3,000 licensed nurses and 100+ doctors, Hydreight aims to capitalize on the global weight loss market, projected to exceed $400 billion by 2030. The company has engaged GRA Enterprises for a three-month term to provide marketing and awareness services for US$30,000.
Hydreight Technologies (TSXV: NURS) (OTCQB: HYDTF) has been named to the 2025 TSX Venture 50™ list, recognizing top-performing companies from over 1,600 TSXV issuers based on market capitalization growth, share price appreciation, and trading volume. The mobile clinical network and medical platform also achieved significant recognition in 2024, ranking 9th in Canada and 56th in North America on Deloitte's Technology Fast 500 list.
The company's VSDHOne telemedicine and e-commerce platform is now fully operational across all 50 U.S. states. CEO Shane Madden highlighted their commitment to innovation in mobile healthcare and telemedicine, focusing on enabling licensed healthcare professionals to deliver care at home, in clinics, and through direct-to-consumer models.
Looking ahead to 2025, Hydreight plans to focus on scaling VSDHOne and the Accelerator Program, optimizing product offerings for higher margins, and exploring 503A and 503B licensing opportunities for vertical integration.
Hydreight Technologies (HYDTF) has expanded its VSDHOne platform by launching Nicotinamide Adenine Dinucleotide (NAD+) therapy in three new delivery formats: patch, injection, and nasal spray. This expansion targets the growing anti-aging market, valued at $73 billion in 2024 and projected to reach $140.94 billion by 2034.
The company now offers NAD+ through three delivery methods: intramuscular/subcutaneous injection for rapid absorption, daily intranasal spray for convenience, and IonToPatch featuring 4-hour wear time and 80 mA/min delivery with 1mL fill volume. NAD+ therapy aims to provide benefits including improved cognitive function, enhanced energy levels, weight management support, and potential neuroprotective effects.
This development strengthens Hydreight's position in providing accessible wellness solutions through its nationwide telehealth network across 50 U.S. states.
Hydreight Technologies (TSXV: NURS, OTCQB: HYDTF) has announced a strategic partnership with The DRIPBaR to launch 'DRIPBaR Direct,' a nationwide direct-to-consumer healthcare initiative. The service will be powered by Hydreight's VSDHOne platform, enabling The DRIPBaR to expand its IV therapy and wellness services across the United States.
The partnership follows a successful pilot phase that demonstrated increased client engagement and operational efficiency. Through the VSDHOne platform, clients can submit health information online, connect with licensed medical professionals remotely, and receive physician-prescribed wellness treatments for self-administration at home.
This collaboration combines Hydreight's mobile clinical network, which operates across 50 states, with The DRIPBaR's expertise in preventive healthcare and IV therapy solutions. The initiative aims to enhance accessibility to personalized health and wellness services, allowing The DRIPBaR to scale its digital health offerings to all franchise locations.
Hydreight Technologies (TSXV: NURS, OTCQB: HYDTF) and Victory Square have announced a $10 million D2C Digital Health Accelerator program through their VSDHOne platform. The initiative aims to support emerging healthcare brands across the United States by providing funding, resources, and platform access.
The program targets companies offering various treatments including skincare, hair loss, sexual health, weight management, and longevity solutions. To qualify, companies must have minimum revenue of $750,000 USD in the last 12 months, US-based operations, and commit to migrating to the VSDHOne platform.
Selected companies will receive funding through a combination of services, cash, and stock, along with access to VSDHOne's telehealth infrastructure, e-commerce solutions, nationwide compliance, marketing support, and a network of healthcare professionals. The initiative addresses inefficiencies in the US healthcare system, projected to reach $7.2 trillion by 2031.
Hydreight Technologies (TSXV: NURS) (OTCQB: HYDTF) reported significant achievements in 2024, including the successful launch of VSDHOne, a telemedicine platform now operating in all 50 states with over 200 licenses sold. The company achieved record financial performance with $6.12 million in Q3 2024 revenue, representing a 54% year-over-year increase, and reached positive adjusted EBITDA.
The company reported $16.58 million in topline revenue for the first 9 months of 2024, a 37% increase compared to 2023. Hydreight was ranked 56th on Deloitte's Technology Fast 500™ in North America and 9th on Deloitte Canada's Technology Fast 50™.
For 2025, Hydreight plans to expand its platform by introducing comprehensive at-home testing services, driving organic growth through strategic acquisitions, and investing in technology partnerships. The company aims to address inefficiencies in the $4.9 trillion U.S. healthcare market through its national network of physicians, nurses, pharmacies, and compliance technology.
Hydreight Technologies (TSXV: NURS, OTCQB: HYDTF) has launched VSDHOne, a comprehensive Direct-to-Consumer healthcare platform now operational across all 50 U.S. states. The platform enables businesses to create their own healthcare brands with features including telemedicine technology, nationwide doctor networks, pharmacy fulfillment, and medical direction.
VSDHOne currently offers approximately 40 products across categories including skincare, hair loss, sexual health, hormone replacement therapy, and GLP-1 weight management. The platform operates on a SaaS model, with customers purchasing state-specific licenses and paying per-order fees. Since its Q2 2024 soft launch, VSDHOne has onboarded over 200 licenses and projects to reach 1,000 licenses by December 2025, with each license expected to process 5-20 orders daily.